Medical Digest & Congress Report

Paul K. Whelton shares his insights on optimizing hypertension management at the American College of Cardiology’s Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:discussion-optimizing-hypertension-management-we-need-new-treatment-and-interventions

Christina Magnussen on individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause at the American College of Cardiology’s Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:lifetime-benefit-control-modifiable-risk-factors

Tor Biering-Sørensen presented the analysis of the primary and secondary endpoint results of the DECODE-CKD at the American College of Cardiology’s Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:dapagliflozin-reduced-lvmi-patients-ckd-decode-ckd

Giulia Magnani explains a nurse-coordinated intensive intervention program emphasizing lifestyle and behavioral changes after ACS was associated with a 30% reduction in major adverse CV events for patients, primarily driven by a reduction in nonfatal MI, according to a study presented at the American College of Cardiology’s Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:nurse-led-behavior-changes-after-heart-attack-cut-subsequent-event-risk-30

Luke Laffin on the phase 2b Advance-HTN study of lorundrostat, whose results were reported in a late-breaking clinical trials presentation at the American College of Cardiology’s 2025 Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:lorundrostat-shows-continued-promise-against-uncontrolled-hypertension

Alan Brown shares his insights on lipoprotein(a) and atherosclerotic cardiovascular disease at the American College of Cardiology’s Annual Scientific Session. Why lipoprotein(a) matters for clinical decisions and patient risk?

Video: https://medicaldigest.org/scientific-contents/interview:shifting-paradigm-lipoprotein-cardiovascular-disease

Raj Makkar explains data from 500 patients treated for aortic regurgitation with the Trilogy transcatheter aortic valve implantation system, point towards positive safety and efficacy outcomes with the device, alongside favourable valve performance at up to two years, according to a study presented at the American College of Cardiology’s Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:align-ar-reports-positive-outcomes-dedicated-tavi-device-aortic-regurgitation

Ankeet S. Bhatt shares his insights how real-world evidence and implementation science can improve ASCVD care at the American College of Cardiology’s Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:evidence-generation-implementation-tackling-unmet-need-ascvd

Heather L. Gornik shares her insights on future of care for patients with peripheral artery disease with the 2024 guidelines'.

Video: https://medicaldigest.org/scientific-contents/interview:stepping-future-care-patients-peripheral-artery-disease-2024-guidelines-report-acc25

2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Stefan D. Anker explains among iron-deficient patients with heart failure with reduced ejection fraction, receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a study presented at the American College of Cardiology’s Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:intravenous-iron-offers-some-benefits-some-patients-heart-failure